Press Release: Novartis receives positive CHMP -2-

References

1. Zeiser R, et al. Ruxolitinib for Glucocorticoid-Refractory Chronic

Graft-versus-Host Disease (REACH3). New England Journal of Medicine; July

2021.

2. Zeiser, R, et al. Ruxolitinib for Glucocorticoid-Refractory Acute

Graft-versus-Host Disease (REACH2). New England Journal of Medicine.

April 2020.

3. Leukemia and Lymphoma Society. Graft-Versus-Host Disease Overview. 2021.

Available at:

https://www.lls.org/treatment/types-treatment/stem-cell-transplantation/graft-versus-host-disease

4. Jaglowski SM, et al. Graft-versus-Host Disease: Why Haven't We Made More

Progress? Curr Opin Hematol. 2014;21(2):141-147

5. Ferrara JL., et al. Graft-versus-host disease. Lancet.

2009;373(9674):1550-1561.

6. Zeiser R., et al. Pathophysiology of Chronic Graft-versus-Host Disease

and Therapeutic Targets. N Engl J Med. 2017 Dec 28;377(26):2565-2579

7. Jagasia MH, et al. National Institutes of Health Consensus Development

Project on Criteria for Clinical Trials in Chronic Graft-versus-Host

Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol

Blood Marrow Transplant. 2015.

8. Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic

treatment of acute graft-versus-host disease: recommendations of the

American Society of Blood and Marrow Transplantation. Biol Blood Marrow

Transplant. 2012;18(8):1150-1163.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Amy Wolf Michael Billings

Novartis External Communications Novartis Hematology Communications

+41 79 576 0723 (mobile) +1 862 788 8656 (direct)

Amy.Wolf@novartis.com +1 201 400 1854 (mobile)

Michael.Billings@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +4 16 132 43809 Alina Levchuk +1 862 778 3372

Isabella Zinck +41 61 324 7188 Parag Mahanti +1 973-876-4912

(END) Dow Jones Newswires

March 25, 2022 08:09 ET (12:09 GMT)